In a phase II trial conducted on patients with NASH, liraglutide, a synthetic agonist of glucagon-like peptide-1 (GLP-1) approved for the treatment of T2DM, showed a resolution of inflammatory activity in 39% of cases along with a weight reduction of 15% from the initial value [13]. Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.